Caught on the wrong foot
24/06/20 -"Solvay’s €1.5bn impairment of the back of the current challenging business situation is the price the current management has to pay for the predecessor’s expensive decisions. The ..."
Pages
62
Language
English
Published on
24/06/20
You may also be interested by these reports :
12/11/25
1Q25/26: Sales lower but EBITDA better than expected by us as well as by the market – FY25/26E guidance confirmed
11/11/25
K+S reported mixed Q3 2025 results, with sales supported by strong pricing and EBITDA benefiting from a low base, although sales missed expectations. ...
10/11/25
Solvay remained under pressure in Q3 2025 amid persistent macroeconomic headwinds. Chinese overcapacity continued to weigh on soda ash sales, though ...
07/11/25
Arkema’s Q3 2025 results were a mixed bag. Investor sentiment is likely supported by guidance matching consensus and management’s optimistic ...